Articles tagged with Parkinsons Disease
Researchers have found that a drug used to treat enlarged prostate may slow the progression of Parkinson's disease. Using big data and bench science, they discovered that terazosin can block cell death by activating an enzyme called PGK1, which is critical for cellular energy production.
A recent study by Radboud University Medical Center found that exercising at home using motivating apps significantly improves cardiovascular fitness and motor disability in Parkinson's patients. The cycling exercise program was more effective than stretching exercises alone, with a notable impact on disease progression.
Parkinson's disease is a neurodegenerative disorder characterized by motor and cognitive impairments. Scientists listed ways of applying genetic engineering to study and treat the disease, including manipulating mitochondria and iron homeostasis. CRISPR technology holds promise for finding new effective treatments.
The new guideline offers evidence-based recommendations to improve the standard of care for individuals with Parkinson's disease in Canada. It includes a new section on palliative care, highlighting the need to consider patients' quality of life throughout all phases of the disease.
Researchers at Hebrew University have developed an MRI technique that can detect molecular changes in the brain, allowing for early disease diagnosis and treatment. This non-invasive method provides biological readouts of brain tissue, enabling doctors to compare scans over time and differentiate between healthy and diseased tissue.
A study by Purdue University researchers suggests that urine analysis can provide faster diagnosis and treatment for traumatic brain injuries, which could lead to improved outcomes for soldiers and athletes. The test checks for elevated levels of acrolein in the urine within seven days of injury.
Researchers at Osaka University used X-ray imaging to visualize Lewy bodies in post-mortem brains and found α-synuclein aggregates with cross-β structure. This discovery supports the idea that Parkinson's disease is a systemic amyloidosis, with implications for diagnosis and treatment.
Researchers at Aarhus University have found evidence that Parkinson's disease may arise in the intestinal system, with harmful proteins like alpha-synuclein migrating to the brain and heart. This new study suggests that understanding how the disease starts could lead to more effective treatments.
Researchers at Vienna University of Technology have successfully incorporated individual metal atoms into a surface, enabling precise control over their chemical behavior. This breakthrough enables the creation of more efficient catalysts for environmentally friendly processes.
A novel study found that fatigue symptoms in Parkinson's Disease are associated with low diastolic blood pressure throughout the day. This association may lead to the development of new treatments targeting DBP without exacerbating cardiovascular effects.
Research published in JNeurosci suggests that estrogen may protect movement neurons from Parkinson's disease, with brain-selective estrogen treatment reducing alpha-synuclein breakdown and severe symptoms in male mice. Female mice also showed less severe symptoms at a later age, indicating potential benefits of estrogen-based treatments.
A new treatment could protect brain cells affected by Parkinson's disease, potentially slowing or stopping its progression. Dr Heather Mortiboys and her team will modify drug compounds that boost cell function in people living with Parkinson's.
Researchers have made a groundbreaking discovery about the alpha-synuclein protein's function in repairing DNA breaks, which may lead to new treatments for Parkinson's disease and other neurodegenerative disorders. The study reveals that alpha-synuclein plays a critical role in binding broken strands of DNA within the cell's nucleus.
Researchers developed neuro biomarkers to create 'smart' deep brain stimulators, adapting to Parkinson's disease patient needs. The technology responds to fluctuating symptoms in real-time, improving the therapy.
A molecule called GM1 ganglioside has been shown to inhibit the toxic effects of alpha-synuclein, a protein that forms clumps in Parkinson's disease. This discovery supports GM1 as a potential treatment for slowing disease progression and improving motor symptoms.
The Luxembourg Parkinson's Study aims to understand the disease mechanism and develop better treatments through a unique approach. By including 800 patients and a control group, researchers will monitor their progress annually to find new biomarkers and test personalized therapies.
Researchers discover that a gut infection can trigger symptoms of Parkinson's disease, suggesting an immune component to the disease. The study found that infection caused auto-immunity, leading to the killing of dopaminergic neurons.
Researchers at DZNE associate oxidative stress with the spreading of abnormal alpha-synuclein protein in Parkinson's disease, a neurodegenerative disorder. The findings suggest that oxidative stress may trigger the formation and aggregation of toxic alpha-synuclein species, leading to progressive pathology and neuronal damage.
A new study published in the European Journal of Neurology found that active sexual life is associated with reduced disability and improved quality of life in men with early Parkinson's disease. The analysis of 355 patients over two years suggests that exploring a patient's sexual life could be beneficial for their treatment.
A new study reveals that protein-linked sugars play a critical role in the uptake of alpha-synuclein proteins, which are associated with Parkinson's disease. The research identifies neurexin 1β as a key regulator in this process and suggests potential therapeutic targets for treating the disease.
Over a 40-year period, Antarctic sea ice coverage increased gradually until 2014 before declining sharply between 2014 and 2017. This trend is more pronounced than observed in the Arctic over the same time frame, with implications for climate modeling and understanding.
Parkinson's UK is partnering with NRG Therapeutics to develop a potential drug that could safeguard dopamine cells and slow down the progression of Parkinson's. The partnership will support the identification of novel molecules to protect mitochondria within dopamine-producing cells.
Researchers at Johns Hopkins Medicine found evidence that Parkinson's disease originates in the gut and travels up the brain's neurons. The study used mice with misfolded alpha-synuclein protein, which causes nerve cell death, to demonstrate the connection.
A team of researchers refutes the long-held common thesis that Parkinson's disease is caused by deposits of insoluble fibrils consisting of alpha-synculein. Instead, they found that Lewy bodies contain mainly membrane fragments, lipids, and other cellular material.
Researchers developed a mouse model that recapitulates Parkinson's disease's progression, showing how misfolded protein α-synuclein spreads from the gut to the brain. The study supports Braak's hypothesis and suggests potential therapeutic targets.
Researchers have found an enzyme in the body that metabolizes compounds from tobacco smoke, alcohol, and certain foods into chemicals that trigger Parkinson's disease. Mitochondrial CYP2D6 is a promising new target for treating idiopathic Parkinson's disease.
Researchers at King's College London have identified the earliest signs of Parkinson's disease in the brain, many years before symptoms appear. The study found changes to the serotonin system as a key early warning signal for the disease.
Researchers investigated mirror activity in healthy humans and found that amplitude grows with repetition, while latency decreases. This inverse relation may be linked to fatigue-induced inhibitory mechanisms failure.
Researchers developed a novel technique using transcranial ultrasound and microbubbles to open the blood-brain barrier, enabling drugs to penetrate the brain and restore dopaminergic pathways. The method has been approved by FDA for clinical trials in Alzheimer's patients and shows promise for treating Parkinson's disease at early stages.
Researchers track early stages of alpha-synuclein protein aggregation in Parkinson's disease, which can lead to significant delay in disease progression. The study's novel method using super-resolution microscopy and advanced analysis has the potential to detect disease progression before symptoms appear.
Researchers have found that anle138b can reduce alpha-synuclein clumps, restore dopamine levels and stop the progression of Parkinson's. Early treatment may be crucial in stopping the condition in its tracks.
A research team from Osaka University has developed a novel gene therapy approach that targets α-synuclein, a protein associated with Parkinson's disease. By using amido-bridged nucleic acid-modified antisense oligonucleotides, the treatment effectively decreases α-synuclein production and reduces disease severity in mice models.
The National Institutes of Health has awarded a $3 million grant to the Cleveland Clinic to conduct a multi-site clinical trial investigating the long-term effects of aerobic exercise on slowing Parkinson's disease progression. The CYCLE trial aims to determine if high-intensity aerobic exercise can slow disease advancement.
Parkinson's disease can spread throughout the brain via tiny channels, where harmful protein aggregates bind and 'hitch a lift' with channel-forming proteins. This process involves specific proteins called connexins, which create small channels between cells.
A national Taiwanese health database study found people with bipolar disorder were nearly seven times as likely to develop Parkinson's disease as those without the condition. The risk was higher for those hospitalized more frequently, developing the disease at a younger age.
Researchers discovered a novel noninvasive electrophysiological biomarker for Parkinson's disease using scalp electrodes and electroencephalography (EEG). The approach showed promise for developing wearable technology to monitor disease-related brain activity at home.
A study from the University of Oregon suggests that specific angles and sharpness of brain waves in unfiltered EEG data may indicate Parkinson's disease. Researchers used raw, unfiltered beta waves to distinguish between patients on and off medication, providing a potentially new approach for diagnosis and treatment.
Parkin's activity depends on recruitment and activation by proteins such as PINK1 and MITOL. The discovery of MITOL's role in tagging damaged mitochondria could lead to improved therapies for Parkinson's disease.
Researchers have identified two cell populations in the substantia nigra that control distinct phases of locomotion. The study reveals a critical role for these populations in maintaining correct movement, and their dysfunction may contribute to Parkinson's disease symptoms.
Researchers found a clear association between appendix removal and development of Parkinson's disease, with patients being over three times more likely to develop the condition. The study analyzed over 62 million patient records and found similar risk levels across all age groups.
Researchers at Osaka University developed a fully automated tool to assess α-synuclein aggregation in cerebrospinal fluid using ultrasonication. The HANABI device can accurately detect patients with Parkinson's disease and has potential for early diagnosis and treatment assessment.
A phase 3 study involving 336 participants found that isradipine did not slow the progression of Parkinson's symptoms over three years. Researchers will continue to work on finding a treatment for the disease despite negative results.
A new study suggests that older adults with poor sense of smell may be at a 46% higher risk for death at 10 years and 30% at 13 years compared to those with good smell. Poor sense of smell is linked to higher mortality in both healthy and unhealthy individuals, with most of the risk remaining unexplained.
A commonly used blood pressure medication has shown potential in slowing the progression of neurodegenerative diseases such as Parkinson's and dementia. The study, published in Nature Communications, found that felodipine induced autophagy in mice with Huntington's disease and zebrafish models of dementia.
A new study reveals that neurofeedback can strengthen neural connections and communication among brain areas in under 1 hour, paving the way for optimizing therapeutic approaches against stroke and Parkinson's. The technique showed increased integrity of the corpus callosum and strengthened neural networks controlling body movements.
The €50 million MOBILISE-D project aims to develop a system using small sensors to monitor mobility and assess health. It will enable personalized healthcare, predictive diagnosis, and improved treatment for conditions like COPD, Parkinson's disease, and multiple sclerosis.
A new service in the UK uses wearable technology to monitor Parkinson's symptoms, enabling patients and specialists to identify and implement changes to therapy remotely. The project aims to reduce healthcare burden and improve quality of life for people with Parkinson's.
Researchers developed a virtual reality training system to aid people with Parkinson's disease in improving their balance and avoiding obstacles. The six-week program showed significant improvements in obstacle negotiation, balance, and range of motion.
Researchers suggest that bi-directional electrodes can both stimulate and record from deep brain structures, enabling closed-loop DBS for movement and psychiatric disorders. This technology could expand treatment possibilities beyond Parkinson's disease.
Researchers at University of the Basque Country have discovered that vitamin B12 inhibits the LRRK2 enzyme, a key target for developing treatments for hereditary Parkinson's. The study shows promise for a new class of neuroprotective therapies.
Researchers identified specific variations in human leukocyte antigen (HLA) genes associated with increased or decreased risk of Parkinson's disease. A history of cigarette smoking modified these associations, suggesting a possible explanation for the apparent protective effect of smoking on PD.
A team of researchers discovered the chemicals responsible for the distinctive smell of Parkinson's disease using a 'super smeller'. The finding could lead to an early diagnosis and monitoring of the condition. Hippuric acid, eicosane, and octadecanal were identified as biomarkers in sebum samples from patients with Parkinson's.
Researchers are seeking to recruit 10,000 participants over 60 without Parkinson's for an annual online questionnaire and tests to develop a predictive algorithm. Early detection could lead to treatments that slow or prevent the condition's progression.
A new study from Iowa State University researchers explores the biological processes by which exposure to metals can contribute to Parkinson's-like symptoms. The study found that manganese combines with a protein called alpha-synuclein, leading to misfolded proteins and a neurodegenerative response.
A €7 million Parkinson's research project, PD-MitoQUANT, will be coordinated by RCSI to deepen understanding of the disease and develop new treatments. The project aims to increase knowledge of how cells in the brain become damaged in Parkinson's, with a focus on mitochondria.
A new study suggests that deep brain stimulation boosts the number and strength of mitochondria in brain cells, which may help reduce Parkinson's symptoms. The treatment, used for late-stage Parkinson's disease, involves surgically implanting thin wires into the brain to deliver small electric pulses.
Researchers found that nilotinib increases dopamine levels by reducing toxic alpha-synuclein protein, allowing normal dopamine release. The study also showed a significant reduction in alpha-synuclein levels and increased TREM-2 activity, indicating an elevated immune response against misfolded proteins.
Researchers have successfully pharmacologically activated Nurr1, a key molecule implicated in Parkinson's disease, offering a potential new treatment strategy. The breakthrough discovery provides valuable leads for developing drugs to restore proper dopamine balance and slow the progression of the disease.
Researchers at Wake Forest Baptist Health will investigate deep brain stimulation as a potential therapeutic approach for Alzheimer's disease, building on previous studies that showed significant improvements in cognitive function in young nonhuman primates. The five-year study aims to determine if DBS can improve memory and counteract...
A Michigan State University researcher is investigating the role of pesticides in olfactory impairment and their relevance to neurodegenerative diseases such as Alzheimer's and Parkinson's. Researchers will assess over 2,200 farmers using a standard smell test and conduct home visits to evaluate cognitive function and motor symptoms.